A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2018
At a glance
- Drugs ONO 7268MX2 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 20 Jan 2018 Results assessing tolerability of ONO-7268MX2 presented at the 2018 Gastrointestinal Cancers Symposium
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.